ReviewCureus2023
Acetaminophen: A Liver Killer or Thriller.
Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Association of serum acetaminophen levels with hepatorenal toxicity: A prospective observational study in Tripura, India.Indian journal of pharmacology · 2026Observational
- Traveling with chronic viral hepatitis.Tropical diseases, travel medicine and vaccines · 2026Review
- The use and misuse of non-steroidal anti-inflammatory drugs (Ibuprofen) and paracetamol among mothers who presented with their children in health facilities in Enugu, South‒East Nigeria.BMC public health · 2026Article
- Integrative Migraine Therapy: From Current Concepts to Future Directions-A Plastic Surgeon's Perspective.Medicina (Kaunas, Lithuania) · 2025Review
- To use or not to use: Safety of selected painkillers in patients with chronic liver diseases.Clinical and experimental hepatology · 2025Review
- Paracetamol: the potential therapeutic pathways defining its clinical use.Inflammopharmacology · 2025Review
- Alcohol in Daily Products: Health Risks, Cultural Considerations, and Economic Impacts.Risk management and healthcare policy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acetaminophen, or paracetamol, ranks among the most extensively utilized analgesic and antipyretic medications globally. The administration of acetaminophen to individuals with underlying liver disease has long sparked concerns regarding the potential risk of hepatotoxicity. However, the available literature and recommendations consider it a safe option in all forms of liver diseases and is deemed safe when used at recommended doses. This article aims to offer a concise review of the pharmacokinetics, toxicity profile, and the intricate considerations surrounding the safety of acetaminophen in patients with liver disease. By delving into the liver-acetaminophen interactions, we seek to provide a nuanced perspective on the use of acetaminophen in this critical patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.